Inimmune’s focus is to discover and develop disease-modifying immunotherapies. Currently, our pipeline includes two clinical-stage Toll-like receptor (TLR) agonists in immuno-oncology and allergy. Both of these TLR agonists generated disease-modifying therapeutic responses in pre-clinical models. Late-stage pre-clinical programs are focused on developing innate immune agonists as next-generation vaccine adjuvants and discovery-stage projects are centered around novel, non-TLR innate immune agonists and antagonists.
Inimmune is a clinical-stage, fast-moving innovative biotech company focused on the discovery and development of novel immunotherapeutics to treat inflammatory conditions. Our most advanced program, INI-2004 as a disease-modifying allergy therapy, is poised to change the way people use and view immunotherapy. Inimmune also has a deep pipeline of other innate immune modulating clinical and pre-clinical assets to treat other inflammatory diseases, such as cancer and autoimmune conditions, and for use as vaccine adjuvants. Anchoring all of these seemingly disparate disease indications is the innate immune system, where all immune responses begin. Altering the immune response from the first step creates a deep ripple effect, driving sustained and durable change to treat and prevent disease.
Inimmune’s team is passionate about developing disease-modifying immunotherapies for indications with a major unmet medical need. Our dedicated team has advanced INI-2004, a next generation TLR4 agonist, as a “pipeline in a product” : a disease-modifying treatment for all allergic conditions. Our sentinel allergy program uses an intranasal spray of INI-2004 to treat allergic rhinitis. INI-2004 for allergic rhinitis has advanced to phase 2 clinical trials and results from this pivotal trial will guide expansion into food allergies, allergic asthma, and perennial allergies. We are also completing a Phase 1 clinical trial using INI-4001, a synthetic TLR7/8 agonist, to treat solid tumors. At the discovery and pre-clinical stage, Inimmune has a deep pipeline of innate agonists and antagonists that are being developed as disease-modifying immunotherapies for other inflammatory diseases.
Inimmune successfully completed a Phase I clinical trial evaluating the safety and tolerability of INI-2004, a TLR4 agonist, administered as a nasal spray for the treatment of allergic rhinitis in 2024. INI-2004 has now advanced to a Phase II chamber trial to further establish its safety and efficacy for allergic rhinitis patients. Inimmune is planning multiple new allergy trials in 2027 and 2028 to evaluate the full potential of this ground breaking new therapy for patients.
Inimmune is also completing a Phase I clinical trial in oncology using INI-4001, a TLR7/8 agonist. We anticipate completion in the second half of 2026.
We partner with some of the best universities and biotech companies. Want to co-create and develop novel immunotherapeutics to improve human health?
We are a biotech company founded by pharmaceutical industry veterans, focused on developing the next generation of vaccines and immunotherapeutics. We have extensive expertise in synthetic and process chemistry, drug formulation, immunology, and clinical translation. Our goal at Inimmune is to recruit, hire, and maintain a diverse workforce. Equal employment opportunity is good business. Equal opportunity applies to all aspects of our employment, including recruitment, selection, hiring, training, transfer, promotion, termination, compensation, and benefits.
